Gaithersburg, United States
Adaptive Phage Therapeutics (APT), founded in 2016, stands as a pioneering force in addressing the formidable challenge of multi-drug resistant infections within the Biotechnology, Health Care, and Pharmaceutical industries. Their slogan, "To save lives or restore health as a leader in safe, rapidly deployable, cost-effective cures for bacterial infections," encapsulates their mission.
At the core of APT's innovation is PhageBank™, an evolving library of bacteriophage therapies that offer broad-spectrum protection against resistant pathogens. This approach is backed by their proprietary phage susceptibility assay, developed in conjunction with Mayo Clinic Laboratories. Originally birthed from a U.S. Department of Defense biodefense program, APT secured global commercial rights in 2017, swiftly responding to critical patient needs under FDA emergency investigational allowances.
In its most recent financial milestone, APT secured a $12.00M Series B investment on June 13, 2023, with contributions from notable investors including Deerfield Capital Management and the AMR Action Fund. Based in the United States, the company's strategic advancements position it as a promising entity in the fight against antimicrobial resistance, appealing to investors eager to support innovative healthcare solutions.
Techulon Inc.